Weak by the machines: muscle motor protein dysfunction – a side effect of intensive care unit treatment

Acta Physiologica

Volumn 222, Issue 1, 2018, Pages

  Friedrich, O ^a   Diermeier, S ^a   Larsson, L ^b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

critical illness; myofibrillar proteins; preferential myosin loss; second harmonic generation microscopy; skeletal muscle

Indexed keywords

MYOSIN; MOLECULAR MOTOR; MUSCLE PROTEIN; STEROID;

ANIMAL; ARTIFICIAL VENTILATION; HUMAN; IMMOBILIZATION; INTENSIVE CARE; INTENSIVE CARE UNIT; METABOLISM; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE; ATROPHY; CLINICAL FEATURE; CRITICAL ILLNESS; DENERVATION; MECHANOTRANSDUCTION; MORPHOMETRY; MUSCLE CELL; MUSCLE CONTRACTILITY; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN METABOLISM; PROTEIN QUALITY; REVIEW; SECOND HARMONIC GENERATION MICROSCOPY; SIGNAL TRANSDUCTION;

ANIMALS; CRITICAL CARE; HUMANS; IMMOBILIZATION; INTENSIVE CARE UNITS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOSINS; RESPIRATION, ARTIFICIAL;

EID: 85018957166     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12885     Document Type: Review

References (86)

1. Berchtold MW, Brinkmeier H, Muntener M: Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 80: 1215–1265, 2000.
2. Finsterer J, Loscher WN, Wanschitz J, Quasthoff S, Grisold W: Secondary myopathy due to systemic diseases. Acta Neurol Scand 134: 388–402, 2016.
3. Larsson L, Friedrich O: Critical illness myopathy (CIM) and ventilator-induced diaphragm muscle dysfunction (VIDD): acquired myopathies affecting contractile proteins. Compr Physiol 7: 105–112, 2017.
4. Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, Larsson L: The Sick and the Weak: neuropathies/Myopathies in the Critically Ill. Physiol Rev 95: 1025–1109, 2015.
5. Fan E, Cheek F, Chlan L, Gosselink R, Hart N, Herridge MS, Hopkins RO, Hough CL, Kress JP, Latronico N, Moss M, Needham DM, Rich MM, Stevens RD, Wilson KC, Winkelman C, Zochodne DW, Ali NA, ATS Committee on ICU-acquired weakness in adults; American Thoracic Society: An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med 190: 1437–1446, 2014.
6. Khan J, Harrison TB, Rich MM, Moss M: Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 67: 1421–1425, 2006.
7. Aare S, Ochala J, Norman HS, Radell P, Eriksson LI, Goransson H, Chen YW, Hoffman EP, Larsson L: Mechanisms underlying the sparing of masticatory versus limb muscle function in an experimental critical illness model. Physiol Genomics 43: 1334–1350, 2011.
8. Akkad H, Corpeno R, Larsson L: Masseter muscle myofibrillar protein synthesis and degradation in an experimental critical illness myopathy model. PLoS One 9: e92622, 2014.
9. Ochala J, Larsson L: Effects of a preferential myosin loss on Ca2+ activation of force generation in single human skeletal muscle fibres. Exp Physiol 93: 486–495, 2008.
10. Larsson L, Li X, Edstrom L, Eriksson LI, Zackrisson H, Argentini C, Schiaffino S: Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 28: 34–45, 2000.
11. Llano-Diez M, Renaud G, Andersson M, Marrero HG, Cacciani N, Engquist H, Corpeno R, Artemenko K, Bergquist J, Larsson L: Mechanisms underlying ICU muscle wasting and effects of passive mechanical loading. Crit Care 16: R209, 2012.
12. Williams AB, Decourten-Myers GM, Fischer JE, Luo G, Sun X, Hasselgren PO: Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 13: 1435–1443, 1999.
13. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE: Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115–123, 2004.
14. Llano-Diez M, Gustafson AM, Olsson C, Goransson H, Larsson L: Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genom 12: 602, 2011.
15. Ochala J, Ahlbeck K, Radell PJ, Eriksson LI, Larsson L: Factors underlying the early limb muscle weakness in acute quadriplegic myopathy using an experimental ICU porcine model. PLoS One 6: e20876, 2011.
16. Ochala J, Gustafson AM, Diez ML, Renaud G, Li M, Aare S, Qaisar R, Banduseela VC, Hedstrom Y, Tang X, Dworkin B, Ford GC, Nair KS, Perera S, Gautel M, Larsson L: Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: underlying mechanisms. J Physiol 589: 2007–2026, 2011.
17. Kalamgi RC, Larsson L: Mechanical Signaling in the Pathophysiology of Critical Illness Myopathy. Front Physiol 7: 23, 2016.
18. Corpeno Kalamgi R, Salah H, Gastaldello S, Martinez-Redondo V, Ruas JL, Fury W, Bai Y, Gromada J, Sartori R, Guttridge DC, Sandri M, Larsson L: Mechano-signalling pathways in an experimental intensive critical illness myopathy model. J Physiol 594: 4371–4388, 2016.
19. Renaud G, Llano-Diez M, Ravara B, Gorza L, Feng HZ, Jin JP, Cacciani N, Gustafson AM, Ochala J, Corpeno R, Li M, Hedstrom Y, Ford GC, Nair KS, Larsson L: Sparing of muscle mass and function by passive loading in an experimental intensive care unit model. J Physiol 591: 1385–1402, 2013.
20. Rossignol B, Gueret G, Pennec JP, Morel J, Rannou F, Giroux-Metges MA, Talarmin H, Gioux M, Arvieux CC: Effects of chronic sepsis on contractile properties of fast twitch muscle in an experimental model of critical illness neuromyopathy in the rat. Crit Care Med 36: 1855–1863, 2008.
21. Buttgereit A, Weber C, Garbe CS, Friedrich O: From chaos to split-ups–SHG microscopy reveals a specific remodelling mechanism in ageing dystrophic muscle. J Pathol 229: 477–485, 2013.
22. Buttgereit A, Weber C, Friedrich O: A novel quantitative morphometry approach to assess regeneration in dystrophic skeletal muscle. Neuromuscul Disord 24: 596–603, 2014.
23. Friedrich O, Both M, Weber C, Schurmann S, Teichmann MD, von Wegner F, Fink RH, Vogel M, Chamberlain JS, Garbe C: Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J 98: 606–616, 2010.
24. Gerovasili V, Stefanidis K, Vitzilaios K, Karatzanos E, Politis P, Koroneos A, Chatzimichail A, Routsi C, Roussos C, Nanas S: Electrical muscle stimulation preserves the muscle mass of critically ill patients: a randomized study. Crit Care 13: R161, 2009.
25. Larsson L, Li X, Berg HE, Frontera WR: Effects of removal of weight-bearing function on contractility and myosin isoform composition in single human skeletal muscle cells. Pflugers Arch 432: 320–328, 1996.
26. Berg HE, Larsson L, Tesch PA: Lower limb skeletal muscle function after 6 wk of bed rest. J Appl Physiol (1985) 82: 182–188, 1997.
27. Borina E, Pellegrino MA, D'Antona G, Bottinelli R: Myosin and actin content of human skeletal muscle fibers following 35 days bed rest. Scand J Med Sci Sports 20: 65–73, 2010.
28. Riley DA, Bain JL, Thompson JL, Fitts RH, Widrick JJ, Trappe SW, Trappe TA, Costill DL: Disproportionate loss of thin filaments in human soleus muscle after 17-day bed rest. Muscle Nerve 21: 1280–1289, 1998.
29. Riley DA, Bain JL, Thompson JL, Fitts RH, Widrick JJ, Trappe SW, Trappe TA, Costill DL: Decreased thin filament density and length in human atrophic soleus muscle fibers after spaceflight. J Appl Physiol (1985) 88: 567–572, 2000.
30. Wollersheim T, Woehlecke J, Krebs M, Hamati J, Lodka D, Luther-Schroeder A, Langhans C, Haas K, Radtke T, Kleber C, Spies C, Labeit S, Schuelke M, Spuler S, Spranger J, Weber-Carstens S, Fielitz J: Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensive Care Med 40: 528–538, 2014.
31. Stibler H, Edstrom L, Ahlbeck K, Remahl S, Ansved T: Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy. Intensive Care Med 29: 1515–1527, 2003.
32. Baldwin KM, Haddad F: Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. J Appl Physiol (1985) 90: 345–357, 2001.
33. Gannon J, Doran P, Kirwan A, Ohlendieck K: Drastic increase of myosin light chain MLC-2 in senescent skeletal muscle indicates fast-to-slow fibre transition in sarcopenia of old age. Eur J Cell Biol 88: 685–700, 2009.
34. Larsson L, Ansved T: Effects of ageing on the motor unit. Prog Neurobiol 45: 397–458, 1995.
35. Gutmann L, Blumenthal D, Gutmann L, Schochet SS: Acute type II myofiber atrophy in critical illness. Neurology 46: 819–821, 1996.
36. Sander HW, Golden M, Danon MJ: Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve 26: 499–505, 2002.
37. Egerman MA, Glass DJ: Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 49: 59–68, 2014.
38. Di Giovanni S, Molon A, Broccolini A, Melcon G, Mirabella M, Hoffman EP, Servidei S: Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55: 195–206, 2004.
39. Constantin D, McCullough J, Mahajan RP, Greenhaff PL: Novel events in the molecular regulation of muscle mass in critically ill patients. J Physiol 589: 3883–3895, 2011.
40. Derde S, Hermans G, Derese I, Guiza F, Hedstrom Y, Wouters PJ, Bruyninckx F, D'Hoore A, Larsson L, Van den Berghe G, Vanhorebeek I: Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med 40: 79–89, 2012.
41. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC: The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 295: E785–E797, 2008.
42. Polla B, Bottinelli R, Sandoli D, Sardi C, Reggiani C: Cortisone-induced changes in myosin heavy chain distribution in respiratory and hindlimb muscles. Acta Physiol Scand 151: 353–361, 1994.
43. Umeki D, Ohnuki Y, Mototani Y, Shiozawa K, Suita K, Fujita T, Nakamura Y, Saeki Y, Okumura S: Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition. PLoS One 10: e0128263, 2015.
44. Macedo AG, Krug AL, Souza LM, Martuscelli AM, Constantino PB, Zago AS, Rush JW, Santos CF, Amaral SL: Time-course changes of catabolic proteins following muscle atrophy induced by dexamethasone. Steroids 107: 30–36, 2016.
45. Tobimatsu K, Noguchi T, Hosooka T, Sakai M, Inagaki K, Matsuki Y, Hiramatsu R, Kasuga M: Overexpression of the transcriptional coregulator Cited2 protects against glucocorticoid-induced atrophy of C2C12 myotubes. Biochem Biophys Res Commun 378: 399–403, 2009.
46. Alamdari N, Smith IJ, Aversa Z, Hasselgren PO: Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 299: R509–R520, 2010.
47. Argadine HM, Mantilla CB, Zhan WZ, Sieck GC: Intracellular signaling pathways regulating net protein balance following diaphragm muscle denervation. Am J Physiol Cell Physiol 300: C318–C327, 2011.
48. Rowan SL, Rygiel K, Purves-Smith FM, Solbak NM, Turnbull DM, Hepple RT: Denervation causes fiber atrophy and myosin heavy chain co-expression in senescent skeletal muscle. PLoS One 7: e29082, 2012.
49. Szabo A, Wuytack F, Zador E: The effect of passive movement on denervated soleus highlights a differential nerve control on SERCA and MyHC isoforms. J Histochem Cytochem 56: 1013–1022, 2008.
50. Loughna PT, Morgan MJ: Passive stretch modulates denervation induced alterations in skeletal muscle myosin heavy chain mRNA levels. Pflugers Arch 439: 52–55, 1999.
51. Bongers KS, Fox DK, Ebert SM, Kunkel SD, Dyle MC, Bullard SA, Dierdorff JM, Adams CM: Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4. Am J Physiol Endocrinol Metab 305: E907–E915, 2013.
52. Ribeiro CB, Christofoletti DC, Pezolato VA, de Cassia Marqueti Durigan R, Prestes J, Tibana RA, Pereira EC, de Sousa Neto IV, Durigan JL, da Silva CA: Leucine minimizes denervation-induced skeletal muscle atrophy of rats through akt/mtor signaling pathways. Front Physiol 6: 73, 2015.
53. Ye J, Zhang Y, Xu J, Zhang Q, Zhu D: FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy. Gene 404: 53–60, 2007.
54. Bertaggia E, Coletto L, Sandri M: Posttranslational modifications control FoxO3 activity during denervation. Am J Physiol Cell Physiol 302: C587–C596, 2012.
55. Zierath JR: Invited review: Exercise training-induced changes in insulin signaling in skeletal muscle. J Appl Physiol (1985) 93: 773–781, 2002.
56. Tajrishi MM, Shin J, Hetman M, Kumar A: DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy. J Biol Chem 289: 19985–19999, 2014.
57. MacDonald EM, Andres-Mateos E, Mejias R, Simmers JL, Mi R, Park JS, Ying S, Hoke A, Lee SJ, Cohn RD: Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition. Dis Model Mech 7: 471–481, 2014.
58. Chen SP, Sheu JR, Lin AC, Hsiao G, Fong TH: Decline in titin content in rat skeletal muscle after denervation. Muscle Nerve 32: 798–807, 2005.
59. Horinouchi H, Kumamoto T, Kimura N, Ueyama H, Tsuda T: Myosin loss in denervated rat soleus muscle after dexamethasone treatment. Pathobiology 72: 108–116, 2005.
60. Rouleau G, Karpati G, Carpenter S, Soza M, Prescott S, Holland P: Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 10: 428–438, 1987.
61. Kraner SD, Wang Q, Novak KR, Cheng D, Cool DR, Peng J, Rich MM: Upregulation of the CaV 1.1-ryanodine receptor complex in a rat model of critical illness myopathy. Am J Physiol Regul Integr Comp Physiol 300: R1384–R1391, 2011.
62. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG: Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110: 3507–3512, 2013.
63. Polge C, Heng AE, Jarzaguet M, Ventadour S, Claustre A, Combaret L, Bechet D, Matondo M, Uttenweiler-Joseph S, Monsarrat B, Attaix D, Taillandier D: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J 25: 3790–3802, 2011.
64. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185: 1083–1095, 2009.
65. Furuno K, Goodman MN, Goldberg AL: Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. J Biol Chem 265: 8550–8557, 1990.
66. Aare S, Radell P, Eriksson LI, Akkad H, Chen YW, Hoffman EP, Larsson L: Effects of corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. Physiol Genomics 45: 312–320, 2013.
67. Norman H, Kandala K, Kolluri R, Zackrisson H, Nordquist J, Walther S, Eriksson LI, Larsson L: A porcine model of acute quadriplegic myopathy: a feasibility study. Acta Anaesthesiol Scand 50: 1058–1067, 2006.
68. Banduseela VC, Ochala J, Chen YW, Goransson H, Norman H, Radell P, Eriksson LI, Hoffman EP, Larsson L: Gene expression and muscle fiber function in a porcine ICU model. Physiol Genomics 39: 141–159, 2009.
69. Banduseela VC, Chen YW, Kultima HG, Norman HS, Aare S, Radell P, Eriksson LI, Hoffman EP, Larsson L: Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. Physiol Genomics 45: 477–486, 2013.
70. Schiaffino S, Reggiani C: Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 76: 371–423, 1996.
71. Ochala J, Renaud G, Llano Diez M, Banduseela VC, Aare S, Ahlbeck K, Radell PJ, Eriksson LI, Larsson L: Diaphragm muscle weakness in an experimental porcine intensive care unit model. PLoS One 6: e20558, 2011.
72. Larsson L: Experimental animal models of muscle wasting in intensive care unit patients. Crit Care Med 35: S484–S487, 2007.
73. Larsson L: Acute quadriplegic myopathy: an acquired “myosinopathy”. Adv Exp Med Biol 642: 92–98, 2008.
74. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704–1708, 2001.
75. Ruderman NB, Berger M: The formation of glutamine and alanine in skeletal muscle. J Biol Chem 249: 5500–5506, 1974.
76. Friedrich O: Critical illness myopathy: what is happening? Curr Opin Clin Nutr Metab Care 9: 403–409, 2006.
77. Gore DC, Wolfe RR: Metabolic response of muscle to alanine, glutamine, and valine supplementation during severe illness. JPEN J Parenter Enteral Nutr 27: 307–314, 2003.
78. Dutka TL, Verburg E, Larkins N, Hortemo KH, Lunde PK, Sejersted OM, Lamb GD: ROS-mediated decline in maximum Ca2+-activated force in rat skeletal muscle fibers following in vitro and in vivo stimulation. PLoS One 7: e35226, 2012.
79. Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, Sejersen T, Richard I, Edström L, Ehler E, Udd B, Gautel M: The kinase domain of titin controls muscle gene expression and protein turnover. Science 308: 1599–1603, 2005.
80. Hornberger TA, Sukhija KB, Chien S: Regulation of mTOR by mechanically induced signaling events in skeletal muscle. Cell Cycle 5: 1391–1396, 2006.
81. Jiroutkova K, Krajcova A, Ziak J, Fric M, Waldauf P, Dzupa V, Gojda J, Nemcova-Furstova V, Kovar J, Elkalaf M, Trnka J, Duska F: Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness. Crit Care 19: 448, 2015.
82. Griffiths RD, Palmer TE, Helliwell T, MacLennan P, MacMillan RR: Effect of passive stretching on the wasting of muscle in the critically ill. Nutrition 11: 428–432, 1995.
83. Friedrich O, Hund E, Weber C, Hacke W, Fink RH: Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251: 53–65, 2004.
84. Llano-Diez M, Cheng AJ, Jonsson W, Ivarsson N, Westerblad H, Sun V, Cacciani N, Larsson L, Bruton J: Impaired Ca(2+) release contributes to muscle weakness in a rat model of critical illness myopathy. Crit Care 20: 254, 2016.
85. Friedrich O, Yi B, Edwards JN, Reischl B, Wirth-Hucking A, Buttgereit A, Lang R, Weber C, Polyak F, Liu I, von Wegner F, Cully TR, Lee A, Most P, Volkers M: IL-1alpha reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy? Am J Respir Cell Mol Biol 50: 1096–1106, 2014.
86. Salah H, Li M, Cacciani N, Gastaldello S, Ogilvie H, Akkad H, Namuduri AV, Morbidoni V, Artemenko KA, Balogh G, Martinez-Redondo V, Jannig P, Hedstrom Y, Dworkin B, Bergquist J, Ruas J, Vigh L, Salviati L, Larsson L: The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med 8: 350ra103, 2016.